



12 December 2018

Mr Dale Allen
Senior Adviser, Listings Compliance (Perth)
ASX Compliance Pty Ltd
Level 40, Central Park
152-158 St Georges Terrace
PERTH WA 6000

By Email: Dale.Allen@asx.com.au

Dear Mr Allen

Exopharm Limited – Updated statement of commitments and pro-forma statement of financial position

We refer to ASX's letter to Jackson McDonald dated 4 December 2018 pursuant to which ASX provides conditional approval for the admission of Exopharm Limited's (**Company**) shares to official quotation on ASX (**Approval Letter**) and confirm the following:

1. **Paragraph 2.2.7: Updated statement of commitments**

- (a) An updated statement of commitments based on the actual amount of funds raised under the Prospectus:

Exopharm intends to use funds of approximately \$400,000 cash on hand as at the Prospectus Date, and the actual funds raised from the Offer of \$7,000,000, as detailed in: **Appendix A**

2. **Paragraph 2.2.8: Updated pro-forma statement of financial position**

- (a) An updated pro-forma statement of financial position based on the actual amount of funds raised under the Prospectus

An updated statement of commitments based on the actual amount of funds raised under the Prospectus is detailed in: **Appendix B**

Yours faithfully

A handwritten signature in black ink, appearing to read "DP", written over a light grey rectangular background.

David Parker
Non-Executive Director and Company Secretary
Exopharm Limited

Appendix A: Updated statement of commitments

	Actual Funds Raised of \$7,000,000 Year 1	Actual Funds Raised of \$7,000,000 Year 2	Actual Funds Raised of \$7,000,000 Total Year 1 and 2	% Based on Actual Funds Raised of \$7,000,000
Funds available				
Cash on hand	\$400,000	-	\$400,000	5.4%
Funds from the Offer	\$7,000,000	-	\$7,000,000	94.6%
Total funds available	\$7,400,000	-	\$7,400,000	100%
Use of funds				
Development Program				
Manufacture	\$1,120,000	\$724,000	\$1,845,000	24.9%
Clinical programs	\$722,000	\$1,250,000	\$1,973,500	26.7%
Supporting research and development activities	\$285,000	\$645,000	\$927,000	12.5%
Other LEAP Technology Opportunities	\$145,000	\$105,000	\$250,000	3.4%
Reimbursement of prior LEAP Technology expenses	\$250,000	-	\$250,000	3.4%
Costs of the Offer	\$654,000	-	\$654,000	8.8%
General working capital	\$870,000	\$630,000	\$1,500,000	20.3%
Total	\$4,046,000	\$3,354,000	\$7,400,000	100%

The above should be read in conjunction with the Prospectus dated 6 November 2018.

Appendix B: Updated pro-forma statement of financial position

Exopharm Limited

As at 30 June 2018

	<i>Audited Historical</i> \$	<i>Subsequen t Events</i> \$	<i>Proforma Adjustments (\$7,000,000 funds raised)</i> \$	<i>Reviewed Proforma (\$7,000,000 funds raised)</i> \$
CURRENT ASSETS				
Cash and cash equivalents	52,401	500,000	6,096,000	6,648,401
Trade and other receivables	60,380	60,000	-	120,380
TOTAL CURRENT ASSETS	112,781	560,000	5,162,000	6,768,781
NON-CURRENT ASSETS				
Property and equipment	20,478	80,000	-	100,478
Intangible assets	175,000	(100,000)	250,000	325,000
TOTAL NON-CURRENT ASSETS	195,478	(20,000)	250,000	425,478
TOTAL ASSETS	308,259	540,000	5,412,000	7,194,259
CURRENT LIABILITIES				
Accounts payable and other current liabilities	215,527	(145,127)	-	70,400
TOTAL CURRENT LIABILITIES	215,527	(145,127)	-	70,400
NON-CURRENT LIABILITIES				
Other non-current liabilities	100,000	(100,000)	-	-
TOTAL NON-CURRENT LIABILITIES	100,000	(100,000)	-	-
TOTAL LIABILITIES	315,527	(245,127)	-	70,400
NET ASSETS/(LIABILITIES)	(7,268)	785,127	5,412,000	7,123,859
EQUITY				
Issued capital	169,090	1,125,000	6,346,000	7,640,090
Accumulated losses	(176,358)	(339,873)	-	(516,231)
TOTAL EQUITY/(DEFICIENCY)	(7,268)	785,127	5,412,000	7,123,859

The above should be read in conjunction with the accompanying notes detailed in the Prospectus dated 6 November 2018.